Raltegravir (MK-0518) targets integrase, an HIV enzyme that integrates the viral genetic material into human chromosomes, a critical step in the pathogenesis of HIV.
Adooq's Raltegravir (MK-0518) has been cited by 3 publications
Joanna Ireland, .et al. , Front Microbiol, 2024, Mar 20:15:1385775 PMID: 38572241
Michal S Barski, .et al. , Nat Commun, 2021, Aug 17;12(1):4996 PMID: 34404793
Lea El Khoury, .et al. , PeerJ Preprints, 2019, 7:e27833v1
Biological Activity
Discription
Raltegravir (MK-0518) targets integrase, an HIV enzyme that integrates the viral genetic material into human chromosomes, a critical step in the pathogenesis of HIV.
Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Solubility
In vitro (25°C)
DMSO
80 mg/mL (180.01 mM)
Water
Insoluble
Ethanol
Insoluble
In vivo
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
7 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula: